Abstract
Neuropeptides are found throughout the entire nervous system where they can act as neurotransmitter, neuromodulator or neurohormone. In those functions, they play important roles in the regulation of cognition and behavior. In brain disorders like Alzheimer’s disease (AD), where abnormal cognition and behavior are observed, the study of neuropeptides is particularly interesting since altered neuropeptides can function as biomarkers or as targets for new medication. In this article neuropeptides with relevance to AD are listed and their influence on cognitive and behavioral disturbances is discussed. Findings from human cerebrospinal fluid and brain tissue, and AD mouse models are described and related to the pathophysiology and symptomatology of the disease. In the past, clinical trials with neuropeptides have often failed due to insufficient delivery to the brain. Therefore, new strategies to target the brain with peptide drugs are also covered.
Keywords: Behavior, blood-brain barrier, clinical trial, cognition, drug delivery systems, pathophysiology, therapy.
Current Alzheimer Research
Title:Neuropeptides in Alzheimer’s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities
Volume: 10 Issue: 5
Author(s): Debby Van Dam, Annemie Van Dijck, Leen Janssen and Peter Paul De Deyn
Affiliation:
Keywords: Behavior, blood-brain barrier, clinical trial, cognition, drug delivery systems, pathophysiology, therapy.
Abstract: Neuropeptides are found throughout the entire nervous system where they can act as neurotransmitter, neuromodulator or neurohormone. In those functions, they play important roles in the regulation of cognition and behavior. In brain disorders like Alzheimer’s disease (AD), where abnormal cognition and behavior are observed, the study of neuropeptides is particularly interesting since altered neuropeptides can function as biomarkers or as targets for new medication. In this article neuropeptides with relevance to AD are listed and their influence on cognitive and behavioral disturbances is discussed. Findings from human cerebrospinal fluid and brain tissue, and AD mouse models are described and related to the pathophysiology and symptomatology of the disease. In the past, clinical trials with neuropeptides have often failed due to insufficient delivery to the brain. Therefore, new strategies to target the brain with peptide drugs are also covered.
Export Options
About this article
Cite this article as:
Dam Debby Van, Dijck Annemie Van, Janssen Leen and Deyn Peter Paul De, Neuropeptides in Alzheimer’s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities, Current Alzheimer Research 2013; 10 (5) . https://dx.doi.org/10.2174/1567205011310050001
DOI https://dx.doi.org/10.2174/1567205011310050001 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) Structure-Based Stabilization of an Enzyme: The Case of Penicillin Acylase from Alcaligenes faecalis
Protein & Peptide Letters Introduction from the Editor-In-Chief
Current Neurovascular Research Does Physician Continuity Within a Clinical Trial Increase Retention and Compliance Among Adolescent Smokers?
Adolescent Psychiatry Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Current Alzheimer Research Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds
Current Medicinal Chemistry The Clinical Applications of Intranasal Opioids
Current Drug Delivery Up-Regulation of TLR-4 in the Brain After Ischemic Kidney-Induced Encephalopathy in the Rat
CNS & Neurological Disorders - Drug Targets Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Stereoselectivity in Drug Metabolism: Molecular Mechanisms and Analytical Methods
Current Drug Metabolism Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias
Current Pharmaceutical Biotechnology Postponing Motherhood: A Demographic and Contemporary Issue
Current Women`s Health Reviews Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-induced Hyperalgesia
Current Psychopharmacology Neurogenic Inflammation and Asthma
Inflammation & Allergy - Drug Targets (Discontinued)